SOHO 2021 | Patient selection for CAR-T in ALL
Stephan Grupp
• 2 Sep 2021
Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, explains the selection process and criteria for the treatment of acute lymphoblastic leukemia (ALL) with chimeric antigen receptor (CAR) T-cell therapy. The selection process largely mirrors the criteria currently used for autologous transplantation such as organ function and Dr Grupp explains that selection also heavily depends on disease burden and the likelihood patients are able to benefit and recover from the therapy. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Stephan Grupp, MD, PhD, has participated in consultancy work with and received research support from Novartis.
